Treatment options for hepatobiliary and pancreatic cancer
- PMID: 17493429
- DOI: 10.4065/82.5.628
Treatment options for hepatobiliary and pancreatic cancer
Abstract
Hepatobiliary and pancreatic cancers account for 4% of all cancers in the United States. Traditionally, these cancers have had a high mortality rate and have been poorly responsive to therapy. Because of a growing number of treatment options, patients are now living longer. For hepatocellular carcinoma, a broad number of treatment options are available, including surgery, ablation, embolization, systemic therapy, and liver transplantation. Treatment options for cholangiocarcinoma include surgery, systemic therapy, and liver transplantation. For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers.
Similar articles
-
[A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy].Gan To Kagaku Ryoho. 2011 Nov;38(12):2469-71. Gan To Kagaku Ryoho. 2011. PMID: 22202416 Japanese.
-
Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.World J Gastroenterol. 2009 Sep 28;15(36):4593-5. doi: 10.3748/wjg.15.4593. World J Gastroenterol. 2009. PMID: 19777621 Free PMC article.
-
[The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma].Gan To Kagaku Ryoho. 2009 Nov;36(12):2009-11. Gan To Kagaku Ryoho. 2009. PMID: 20037307 Japanese.
-
The surgical treatment of primary hepatobiliary malignancy.Liver Transpl Surg. 1996 Sep;2(5 Suppl 1):114-30. Liver Transpl Surg. 1996. PMID: 9346711 Review. No abstract available.
-
[Surgical therapy of malignant liver tumors: resection and transplantation].Internist (Berl). 1997 Oct;38(10):963-9. doi: 10.1007/s001080050107. Internist (Berl). 1997. PMID: 9432504 Review. German. No abstract available.
Cited by
-
Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours.Insights Imaging. 2013 Oct;4(5):691-700. doi: 10.1007/s13244-013-0268-2. Epub 2013 Jul 25. Insights Imaging. 2013. PMID: 23884572 Free PMC article.
-
High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition.Am J Transl Res. 2019 Sep 15;11(9):5438-5456. eCollection 2019. Am J Transl Res. 2019. PMID: 31632521 Free PMC article.
-
18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1037-45. doi: 10.1007/s00259-011-1736-x. Epub 2011 Feb 10. Eur J Nucl Med Mol Imaging. 2011. PMID: 21308371
-
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.Int J Oncol. 2016 Mar;48(3):908-18. doi: 10.3892/ijo.2016.3320. Epub 2016 Jan 5. Int J Oncol. 2016. PMID: 26781210 Free PMC article.
-
Scoring systems for the management of oncological hepato-pancreato-biliary patients.Ann Hepatobiliary Pancreat Surg. 2022 Feb 28;26(1):17-30. doi: 10.14701/ahbps.21-113. Ann Hepatobiliary Pancreat Surg. 2022. PMID: 35220286 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical